Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old. This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR). FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in...
✔️ MITRAL VALVE Session ✔️ SOLACI-SOCIME 2022 Scientific Session 👨🏫 Content: 00:07 – Welcoming Words- Dr. Guering Eid Lidt (MEX) 01:26 – Mitral valve replacement – Dr. Ignacio Amat (ESP) 18:15 – Transcatheter treatment of mitral valve regurgitation – Dr. Luis Nombela Franco (ESP) 34:57 – Mitral valve-in-valve – Dr. Guering Eid Lidt (MEX)
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Luis Nombela Franco, entitled “My Best case of Mitral Valve Edge to Edge repair”
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Luis Nombela Franco, entitled “Transcatheter treatment of mitral valve regurgitation”
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Márcio Montenegro, entitled “When is indicated the transcatheter treatment of mitral regurgitation”
During the “Mitral Valve” session (on the first day of the SOLACI-SOCIME 2022 Congress), Dr. Ignacio Amat Santos (SPA) delivered a great talk on transcatheter mitral valve replacement (TMVR). During his presentation, he discussed different scenarios for transcatheter replacement: mitral valve-in-vale, mitral valve-in-ring, mitral valve in MAC, and new devices for non-calcified native valves. When...
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Ignacio Amat Santos, entitled “Mitral valve replacement”
The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were...
Transcatheter mitral valve repair using the edge-to-edge strategy has become a therapeutic alternative for patients with severe primary mitral valve regurgitation (MVG) who are at high or extreme surgical risk. However, both degree of residual regurgitation and gradient after the procedure should be taken into account, as in previous studies the latter was associated with...
The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for...